ErbB2/Her2 Antikörper (pTyr1112)

Produktnummer ABIN1881304

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch ErbB2/Her2 in WB und DB. Er zeigt eine Reaktivität gegenüber Human und wurde in 5+ Publikationen erwähnt.

Kurzübersicht für ErbB2/Her2 Antikörper (pTyr1112) (ABIN1881304)

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser ErbB2/Her2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Dot Blot (DB)

Klon: RB40063

Produktdetails anti-ErbB2/Her2 Antikörper

Bindungsspezifität: pTyr1112

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This ErbB2 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1112 of human ErbB2.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:2000. DB: 1:500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-ErbB2/Her2 Antikörper (ABIN1881304)

Mándoky, Géczi, Bodrogi, Tóth, Csuka, Kásler, Bak: "Clinical relevance of HER-2/neu expression in germ-cell testicular tumors." in: Anticancer research, Vol. 24, Issue 4, pp. 2219-24, (2004) (PubMed).

Contreras, Cobos, Lox: "Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?" in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 10, Issue 3, pp. 271-6, (2004) (PubMed).

Stephens, Hunter, Bignell, Edkins, Davies, Teague, Stevens, OMeara, Smith, Parker, Barthorpe, Blow, Brackenbury, Butler, Clarke, Cole, Dicks, Dike, Drozd, Edwards, Forbes, Foster, Gray, Greenman et al.: "Lung cancer: intragenic ERBB2 kinase mutations in tumours. ..." in: Nature, Vol. 431, Issue 7008, pp. 525-6, (2004) (PubMed).

Wang, Lien, Xia, Chen, Lo, Wang, Ali-Seyed, Lee, Bartholomeusz, Ou-Yang, Giri, Hung: "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2." in: Cancer cell, Vol. 6, Issue 3, pp. 251-61, (2004) (PubMed).

Menendez, Vellon, Mehmi, Oza, Ropero, Colomer, Lupu: "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 29, pp. 10715-20, (2004) (PubMed).

Details zu ErbB2/Her2

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Andere Bezeichnung: ERBB2

Hintergrund: ErbB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.

Molekulargewicht: 137910

NCBI Accession: NP_001005862, NP_004439

UniProt: P04626

Pathways: RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Skeletal Muscle Fiber Development